Business Wire

Shin-Etsu Chemical’s Silicone Division Is Strengthening Its Initiative to Contribute to Carbon Neutrality

1.7.2021 09:15:00 EEST | Business Wire | Press release

Share

The Silicone Division of Shin-Etsu Chemical Co., Ltd. (Head Office: Tokyo; President, Yasuhiko Saitoh) will implement an investment totaling ¥20 billion to help facilitate its efforts to achieve a reduction in the volume of greenhouse gas emissions.

1. Investment for the reduction in the volume of greenhouse gas emissions in our company’s manufacturing processes.

At the Silicone Division’s main manufacturing plant, the Gunma Complex, we will reduce the greenhouse gas emission volume by 14% compare to that of the present time by further increasing the degree of self-sufficiency in our usage of electric power. The investment amount is for a total of ¥10 billion.

2. Capital investment for the reduction in the volume of greenhouse gas emissions in our customers’ manufacturing processes and the increase of our supply capacity of products used in environmentally friendly products.

We will strengthen our supply capacity of products that contribute to the environment. These include modified silicone fluids, silicone rubber for molding, and heat-dissipation thermal interface silicone materials. The investment amount is for a total of ¥10 billion, and it will be implemented at the Gunma Complex.

Shin-Etsu Chemical is carrying out a Carbon Neutral policy as one of the key issues of management. The Silicone Division has developed and is marketing a millable-type of molding silicone rubber that does not require post-cure in its manufacturing process. By using this product, it became possible to reduce the processing time by about 90%, compared to that needed for the conventional product, and it makes possible energy saving and the improvement of productivity for customers. *

In addition, the applications of the low-density type of silicone rubber that realize lighter-weight rubber molded products are growing in many industrial fields such as automobiles and transportation vehicles like airplanes, as well as in other diverse fields such as wearable devices, and this contributes to energy saving by making them lighter-weight. In addition to these two innovative products we are now marketing, we are developing and supplying many silicone products that contribute to the global environment by such means as helping to achieve reductions in the volume of greenhouse gas emissions.

Towards the realization of Carbon Neutral that Japan as well as other major industrial nations are striving to achieve, Shin-Etsu Chemical will further focus on strengthening our efforts to reduce our company’s greenhouse gas emissions, and at the same time, we will develop, produce and supply products that help facilitate the reduction of emissions, starting with for our customers as well as for society as a whole.

*Comparison data for cases when the 2mm-thickness silicone sheets were produced.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For inquires about this matter, please contact:
Shin-Etsu Chemical Co., Ltd.
Public Relations Dept.
Tetsuya Koishikawa
Tel: 03-3246-5091, or from outside Japan: 81-3-3246-5091
Fax: 03-3246-5096, or from outside Japan: 81-3-3246-5096
e-mail: sec-pr@shinetsu.jp
www.shinetsu.co.jp/en/

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces the European Commission Approval of Zynyz ® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 23:42:00 EET | Press release

Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meury, President and Chief Executive Officer, Incyte. “As the first PD-1 immunotherapy approved in Europe in combination with platinum-based chemotherapy in the first-line setting, Zynyz helps expand the standard-of-care options available to clinicians and underscores our commitment to delivering innovative medicines that can have an impact for patients.” The EC decision follows the January 2026 positive opinion received from the European Medicines Agency’s Committee f

Dfns Launches Payouts6.3.2026 22:27:00 EET | Press release

Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i

Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 21:23:00 EET | Press release

Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up

Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 19:30:00 EET | Press release

Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different

Sutherland Launches FinAI Hub to Industrialize Agentic AI for Banking and Financial Services6.3.2026 15:00:00 EET | Press release

Today, Sutherland announced the launch of Sutherland FinAI Hub, an enterprise Agentic AI platform built exclusively for Banking and Financial Services. As financial institutions accelerate AI adoption, many initiatives remain confined to pilots, unable to scale across legacy systems and core operations. Sutherland FinAI Hub is designed to help close that gap. FinAI Hub is an innovation ecosystem where Sutherland works with clients to design, prototype, and scale Agentic AI workflows across core operations. At launch, the platform brings together a large and expanding workforce of domain-trained AI agents purpose-built for financial institutions, supporting functions across retail banking, payments, cards, consumer and commercial lending, servicing, back office, risk and compliance functions. These modular agents can operate independently or be orchestrated across end-to-end workflows spanning onboarding, KYC, AML, fraud, underwriting, payments, disputes, servicing, and collections. For

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye